share_log

Arcutis Biotherapeutics | DEF 14A: Definitive information statements

Arcutis Biotherapeutics | DEF 14A: Definitive information statements

Arcutis Biotherapeutics | DEF 14A：股東委託書決議
美股sec公告 ·  04/26 16:39
Moomoo AI 已提取核心訊息
Arcutis Biotherapeutics, Inc., a Delaware corporation, has announced its Annual Meeting of Stockholders to be held virtually on June 14, 2024. The meeting will address the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, the advisory approval of executive compensation, and other business as may arise. Stockholders as of April 22, 2024, are entitled to vote. The Board recommends voting for the proposed director nominees, the ratification of Ernst & Young LLP, and the approval of executive compensation. The company has also filed its definitive proxy statement with the SEC. Additionally, the company has provided a summary of the compensation of named executive officers and the opportunity for a non-binding advisory vote on executive compensation at the upcoming meeting.
Arcutis Biotherapeutics, Inc., a Delaware corporation, has announced its Annual Meeting of Stockholders to be held virtually on June 14, 2024. The meeting will address the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, the advisory approval of executive compensation, and other business as may arise. Stockholders as of April 22, 2024, are entitled to vote. The Board recommends voting for the proposed director nominees, the ratification of Ernst & Young LLP, and the approval of executive compensation. The company has also filed its definitive proxy statement with the SEC. Additionally, the company has provided a summary of the compensation of named executive officers and the opportunity for a non-binding advisory vote on executive compensation at the upcoming meeting.
特拉華州的一家公司Arcutis Biotherapeutics, Inc. 宣佈其年度股東大會將於2024年6月14日虛擬舉行。會議將討論三名第一類董事的選舉、批准安永會計師事務所爲截至2024年12月31日的財政年度的獨立註冊會計師事務所、高管薪酬的諮詢批准以及可能出現的其他事項。截至2024年4月22日，股東有權投票。董事會建議對擬議的董事候選人進行投票，批准安永會計師事務所，並批准高管薪酬。該公司還向美國證券交易委員會提交了最終委託書。此外，該公司還提供了指定執行官薪酬摘要，並提供了在即將舉行的會議上就高管薪酬進行不具約束力的諮詢投票的機會。
特拉華州的一家公司Arcutis Biotherapeutics, Inc. 宣佈其年度股東大會將於2024年6月14日虛擬舉行。會議將討論三名第一類董事的選舉、批准安永會計師事務所爲截至2024年12月31日的財政年度的獨立註冊會計師事務所、高管薪酬的諮詢批准以及可能出現的其他事項。截至2024年4月22日，股東有權投票。董事會建議對擬議的董事候選人進行投票，批准安永會計師事務所，並批准高管薪酬。該公司還向美國證券交易委員會提交了最終委託書。此外，該公司還提供了指定執行官薪酬摘要，並提供了在即將舉行的會議上就高管薪酬進行不具約束力的諮詢投票的機會。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息